202121 Sep

WiCON Publishes the China Pharmaceutical Guide 2021 (16th Edition)


There has been a significant increase in diagnoses and jump in prescriptions on online healthcare platforms, and accelerated the adoption of AI in CT scans, algorithms for COVID-19 detection in genomic sequencing, and AI-based research platforms for vaccines.Domestic pharma players have increasingly turned to R&D for future growth as they boost fundraising to facilitate M&A, pipeline and expansion, while foreign companies continued to be blessed in 2020 with more new drug approvals, which understandably renewed their hope for the promised land. A slew of MNCs, including Pfizer, Novartis, AstraZeneca, Sanofi, Roche, J&J, Bayer, Fresenius, Novo Nordisk, AbbVie and Takeda, showed their support to the Chinese government by pledging commitments to the country’s market and signing multiple deals at the Third China International Import Expo in November 2020, even as many of them, if not all, were experiencing huge setbacks with recent sales of their flagship off-patent originator brands in China.Structural issues with the Chinese healthcare system continued to haunt the pharmaceutical industry in 2020 and 2021. According to the latest report from The IQVIA Institute, Global Medicine Spending and Usage Trends: Outlook to 2025, which projects the global medicine market, using invoice price levels, to grow at 3–6% CAGR through 2025, reaching about $1.6 trillion in total market size in 2025.The China Pharmaceutical Guide 2021, an indispensable annual reference for MNC pharma executives with China responsibilities for more than a decade, provides various data sets on the Chinese pharmaceutical market and drug consumption patterns from respected sources including IQVIA, SMEI, CPIIC, CPA, Sinohealth, Nicholas Hall and other official sources. The publication, from the publisher of WiCON | Pharma China and covers all aspects of Chinese pharma/healthcare sector, aims to help HQ and local executives at proactive MNCs feel the dynamic and up-to-date pulse of Chinese healthcare in order to stay in the driver seat of their business in the country.Now in its 16th edition, China Pharmaceutical Guide 2021 continues to play an instrumental role in helping executives understand, navigate, manage and lead their pharmaceutical businesses in China.Authored by James J. Shen, a veteran pharmaceutical executive and the Publisher/Chief Editor of Pharma China who has three decades of managing China and Asian pharma businesses as a leading China business consultant, multinational company executive and an entrepreneur.Prepared for the real-world executives to help them navigate through the complex and turbulent Chinese healthcare business environment for success.Comprehensive and latest data on the Chinese pharmaceutical industry and market, the Chinese healthcare sector, drug evaluation and registration, and disease & drug consumption patterns – much of the data made available exclusively by reputable sources to China Pharmaceutical Guide and Pharma China.The China Pharmaceutical Guide 2021 (16th Edition) is presented in four comprehensive volumes, which is organized into the following four volumes:* Volume I – Overview of the Chinese Pharmaceutical & Healthcare Sectors (covering update of China’s business environment, history and structure of the Chinese pharmaceutical industry, Chinese health sector structure and statistics, health insurance sector structure and data, as well as disease and drug consumption patterns);* Volume II – Chinese Pharmaceutical IP and Regulatory Guide (covering the Chinese drug regulatory system overview, summaries of major healthcare/pharmaceutical related laws and regulations, government agencies and industry associations and pharma IP strategies & legal issues);* Volume III – Annual Review, Trends, Opportunities and Strategic Considerations (including a complete review of latest data, business trends, regulatory & IP/legal developments and healthcare reform progress of the Chinese pharmaceutical industry and market in 2020/1H2021, and a large collection of feature articles from industry experts relating to contemporary trends, issues and strategic considerations as well as promising opportunities of the present and future); and* Volume IV – Sales & Marketing, Entry Strategies and Case Studies (covering orientation, models and strategies of pharmaceutical sales, marketing and distribution in China, marketing entry strategies and execution, case studies featuring success stories of MNCs and domestic players, R&D and outsourcing, human resource management and legal/IP issues), as well as appendices with full texts of important healthcare/pharma related policies, laws and regulations.It is thoroughly updated with ample latest data from many reputable sources, abundant analysis by leading industry experts, new regulations and more case studies. Numerous new case studies are added, as existing cases are updated and filtered.All purchasers of the China Pharmaceutical Guide 2021 (16h Edition) will receive one-year complimentary subscription of Pharma China Weekly e-Alert (Premium Edition) which provides a weekly summary of the top Chinese pharmaceutical news and Breaking News Alerts which notifies subscribers of any major unfolding events in the Chinese pharmaceutical and healthcare sectors.For further information, please contact WiCON International Group to request a free promotional PDF containing the executive summary, the table of contents, the lists of tables and charts, and preface.

Source: Pr